C4 Therapeutics Stock Forecast
NASDAQ: CCCCHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 8, 2:39 PM ET
CCCC analyst consensus
Consensus (7 analysts)
strong_buy
Avg. price target
$13.33+364.46%
- Strong buy 1
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 7 Wall Street analysts covering C4 Therapeutics (2026-10-08), 7 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $13.33, with a high estimate of $30.00 and a low estimate of $7.00. The average target implies upside of 364.5% from the current price of $2.87.
The spread between the highest and lowest targets is 328.6%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for CCCC.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 14% |
| Buy | 6 | 86% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $7.00 | +143.90% |
| Average target | $13.33 | +364.46% |
| High target | $30.00 | +945.30% |